Literature DB >> 6731845

Progress curve analysis of adenosine deaminase-catalyzed reactions.

T Spector.   

Abstract

The kinetic constants of the adenosine deaminase-catalyzed conversion of adenosine to inosine were found to be readily obtainable by analyzing the progress curve of a single reaction. A novel inhibitor, 9-(1-hydroxymethyl-3-methylbutyl)adenine, was studied to test the validity of the progress curve method with this enzyme. Estimates of kinetic constants determined by this method were compared to those determined by the conventional initial velocity analysis. The Km and Vmax values for adenosine and the Ki value for the inhibitor were estimated to be 26.1 microM, 1.27 mumol/min/unit of enzyme, and 0.48 microM, respectively, by the initial velocity method, and 29.3 microM, 1.27 mumol/min/unit of enzyme, and 0.52 microM, respectively, by the progress curve analysis. The inhibitor was shown to act competitively with substrate by both methods of analysis. The progress curve experiments were very simple to perform and the constants were calculated (with an interfaced microcomputer) within a few minutes of the completion of each assay.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6731845     DOI: 10.1016/0003-2697(84)90796-6

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Enzyme kinetic studies from progress curves.

Authors:  E I Canela; R Franco
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

2.  Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine.

Authors:  Adrian S Ray; Brenda I Hernandez-Santiago; Judy S Mathew; Eisuke Murakami; Carey Bozeman; Meng-Yu Xie; Ginger E Dutschman; Elizabeth Gullen; Zhenjun Yang; Selwyn Hurwitz; Yung-Chi Cheng; Chung K Chu; Harold McClure; Raymond F Schinazi; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.

Authors:  P A Furman; J Jeffrey; L L Kiefer; J Y Feng; K S Anderson; K Borroto-Esoda; E Hill; W C Copeland; C K Chu; J P Sommadossi; I Liberman; R F Schinazi; G R Painter
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  6-N-substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus.

Authors:  G W Koszalka; D R Averett; J A Fyfe; G B Roberts; T Spector; K Biron; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

5.  Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.

Authors:  V Nair; M H St Clair; J E Reardon; H C Krasny; R J Hazen; M T Paff; L R Boone; M Tisdale; I Najera; R E Dornsife
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside.

Authors:  C U Lambe; A Resetar; T Spector; G W Koszalka; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.